Abbott Labs (ABT) PT Lowered to $125 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Price: $106.20 +1.56%
Rating Summary:
26 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
26 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Barclays analyst Travis Steed lowered the price target on Abbott Labs (NYSE: ABT) to $125.00 (from $150.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Stryker (SYK) PT Lowered to $325 at Piper Sandler
- Freedom Broker Downgrades RPC Inc. (RES) to Sell
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
